These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17394072)

  • 41. Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.
    Kyvernitakis A; Mahale P; Popat UR; Jiang Y; Hosry J; Champlin RE; Torres HA
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):717-722. PubMed ID: 26712592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
    Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
    Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
    Mehta SH; Lucas GM; Mirel LB; Torbenson M; Higgins Y; Moore RD; Thomas DL; Sulkowski MS
    AIDS; 2006 Nov; 20(18):2361-9. PubMed ID: 17117023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of specialty care versus standard retail pharmacies for treatment of hepatitis C.
    Cohen SM; Kwasny MJ; Ahn J
    Ann Pharmacother; 2009 Feb; 43(2):202-9. PubMed ID: 19193591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
    Righi E; Beltrame A; Bassetti M; Lindstrom V; Mazzarello G; Dentone C; Di Biagio A; Ratto S; Viscoli C
    Infection; 2008 Aug; 36(4):358-61. PubMed ID: 18642111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
    Lang JP; Melin P; Ouzan D; Rotily M; Fontanges T; Marcellin P; Chousterman M; Cacoub P;
    Antivir Ther; 2010; 15(4):599-606. PubMed ID: 20587853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initiation of methamphetamine abuse during interferon treatment.
    Lampinen TM; Greatheart MS; Schilder AJ; Kowdley K
    Am J Psychiatry; 2007 Sep; 164(9):1439. PubMed ID: 17728435
    [No Abstract]   [Full Text] [Related]  

  • 48. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.
    La Mura V; De Renzo A; Perna F; D'Agostino D; Masarone M; Romano M; Bruno S; Torella R; Persico M
    J Hepatol; 2008 Oct; 49(4):557-63. PubMed ID: 18678434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current practice of hepatitis C treatment in Southern Italy.
    Stroffolini T; Spadaro A; Guadagnino V; Cosentino S; Fatuzzo F; Galdieri A; Cacopardo B; Scalisi I; Sapienza M; Russello M; Scifo G; Frugiuele P; Foti G; Almasio PL;
    Dig Liver Dis; 2010 Nov; 42(11):822-5. PubMed ID: 20435532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.
    Kawamura Y; Ikeda K; Arase Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2007 Dec; 120(12):1034-41. PubMed ID: 18060923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The recurrence of hepatitis C virus after liver transplantation].
    Nemes B; Sárváry E; Gerlei Z; Fazakas J; Doros A; Németh A; Görög D; Fehérvári I; Máthé Z; Gálffy Z; Pár A; Schuller J; Telegdy L; Fehér J; Lotz G; Schaff Z; Nagy P; Járay J; Lengyel G
    Orv Hetil; 2007 Oct; 148(42):1971-9. PubMed ID: 17932003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants.
    Jeffrey GP; MacQuillan G; Chua F; Galhenage S; Bull J; Young E; Hulse G; O'Neil G
    Hepatology; 2007 Jan; 45(1):111-7. PubMed ID: 17187435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rate and predictors of treatment prescription for hepatitis C.
    Butt AA; Justice AC; Skanderson M; Rigsby MO; Good CB; Kwoh CK
    Gut; 2007 Mar; 56(3):385-9. PubMed ID: 17005764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Management of hepatitis C among drug user patients].
    Moussalli J; Melin P; Wartelle-Bladou C; Lang JP
    Gastroenterol Clin Biol; 2007; 31(8-9 Pt 3):4S51-5. PubMed ID: 17965636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan.
    Chang LJ; Chang HC; Chen PY; Chen CY; Tsai KF; Yean KK; Yang HY; Chen TH; Yu PT; Chou CK; Chen SH
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454360
    [No Abstract]   [Full Text] [Related]  

  • 56. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
    Evon DM; Stewart PW; Amador J; Serper M; Lok AS; Sterling RK; Sarkar S; Golin CE; Reeve BB; Nelson DR; Reau N; Lim JK; Reddy KR; Di Bisceglie AM; Fried MW
    PLoS One; 2018; 13(8):e0196908. PubMed ID: 30067745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
    Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
    Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus.
    Kanwal F; Pyne JM; Tavakoli-Tabasi S; Nicholson S; Dieckgraefe B; Storay E; Goetz MB; Kramer JR; Smith D; Sansgiry S; Tansel A; Gifford AL; Asch SM
    Health Serv Res; 2018 Aug; 53(4):2547-2566. PubMed ID: 28891153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents.
    Woodrell C; Weiss J; Branch A; Gardenier D; Krauskopf K; Kil N; Paredes H; Bichoupan K; Sigel K
    J Addict Med; 2015; 9(5):405-10. PubMed ID: 26291545
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.